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Abstract
Background: A previously published proof of principle phase IIa trial with 113 patients from Kabul showed that
bipolar high-frequency (HF) electro-cauterization (EC) of cutaneous leishmaniasis (CL) ulcers and subsequent moist
wound treatment (MWT) closed 85% of all Leishmania (L.) tropica lesions within 60 days.
Methods: A three-armed phase IIb, randomized and controlled clinical trial was performed in Mazar-e-Sharif. L.
tropica- or L. major-infected CL patients received intradermal sodium stibogluconate (SSG) (Group I); HF-EC followed
by MWT with 0.045% DAC N-055 (Group II); or MWT with 0.045% DAC N-055 in basic crème alone (Group III). The
primary outcome was complete epithelialisation before day 75 after treatment start.
Results: 87 patients enrolled in the trial were randomized into group I (n = 24), II (n = 32) and III (n = 31). The
per-protocol analysis of 69 (79%) patients revealed complete epithelialisation before day 75 in 15 (of 23; 65%)
patients of Group I, in 23 (of 23; 100%) patients of Group II, and in 20 (of 23; 87%) patients of Group III (p = 0.004,
Fisher’s Exact Test). In the per-protocol analysis, wound closure times were significantly different between all
regimens in a pair-wise comparison (p = 0.000039, Log-Rank (Mantel-Cox) test). In the intention-to-treat analysis
wound survival times in Group II were significantly different from those in Group I (p = 0.000040, Log-Rank
(Mantel-Cox) test). Re-ulcerations occurred in four (17%), three (13%) and seven (30%) patients of Group I, II or III,
respectively (p = 0.312, Pearson Chi-Square Test).
Conclusions: Treatment of CL ulcers with bipolar HF-EC followed by MWT with 0.045% DAC N-055 or with DAC
N-055 alone showed shorter wound closure times than with the standard SSG therapy. The results merit further
exploration in larger trials in the light of our current knowledge of in vitro and in vivo activities of chlorite.
Clinicaltrials.gov ID: NCT00996463. Registered: 15th October 2009.
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Background
In developed countries chronic wounds are an advanced
age disease. In Afghanistan, cutaneous leishmaniasis
(CL) ulcers resulting from parasite infections disfigure
non-covered parts of the body especially at younger age.
Advanced age wounds elicit industrial R&D efforts,
whereas particularly in the Near, Middle and Far East
CL wounds constitute a neglected field of clinical re-
search, although their incidence of approximately 0.5%
to 1% is of the same magnitude [1,2].
In 1986, a randomized controlled trial (RCT) has shown
that moist dressing with a sodium chlorite (NaClO2)-
based drug is beneficial for rapid wound cleansing and
granulation [3]. If not further concentrated under vacuum
(which is commonly practiced with industrial NaClO2),
pharmaceutical chlorite contains a chlorine peroxide con-
taminant, formerly called tetradecachlorooxygen (TCDO),
a chemical name refuted by the German Health Authorities
[4]. The chlorine peroxide seems to be important for sys-
temic regenerative effects in stem cell compartments of rats
[5,6]. Recent advances in bacterial heme protein biochemis-
try [7,8] have reformed our understanding of chlorite bio-
chemistry [9] showing that in vivo reactions of chlorite with
heme analogues can either produce hypochlorite, which in
turn can react with H2O2 to form singlet oxygen
1O2, or
which can dismutate to Cl− and 1O2. In animal experiments
with non-thermal (NTP) [10] or cold atmospheric plasma
(CAP) [11] lower μM levels 1O2 have shown to induce
wound healing.
Simple physical wound debridement practised with
bi-polar high frequency electrosurgical cauterisation
(HF-EC) as a first step seemed to be of crucial import-
ance [12] to achieve faster wound healing than obtained
with sodium stibogluconate (SSG) [13]. As recently
advocated [14], special attention should be given to
the wound disease character of Old World Cutaneous
Leishmaniasis (OWCL) lesions with frequent bacterial
and fungal contaminations [15] which are typical for
chronic wounds [16].
Within the present randomized controlled three-armed
clinical trial we investigated the benefit of applying local
wound treatment to OWCL ulcers. The overall aim of
this RCT phase IIb trial in Mazar-e-Sharif, Afghanistan,
was (a) to confirm previous results [12] using bipolar HF-
EC combined with subsequent moist wound treatment
(MWT) with 0.045 % of the pharmaceutical sodium
chlorite solution (DAC N-055); and to directly com-
pare the results (b) with topical anti-parasitic SSG and
(c) with 0.045% DAC N-055 MWT alone, known to
promote tissue regeneration [3,5,6]. The trial was fur-
ther encouraged by the previous successful treatment
of four patients with facial lupoid leishmaniasis, in
whom the topical application of 0.045% DAC N-055
led to a rejuvenation of the faces [17,18].
Methods
Trial design
The study was designed as a mono-centric, three armed,
open label, randomized (1:1:1), controlled, phase IIb trial
with tissue biopsy [19] without any amendments to the
protocol after trial start.
Ethics
Ethical clearance was obtained from the Ethics Committees
of the Medical Faculties of Heidelberg and Erlangen
in Germany and the International Review Board at
the Ministry of Public Health in Kabul, Afghanistan
(Clinicaltrials.gov ID: NCT00996463. Registered: 15th
October 2009). As nearly all patients could neither
read nor write or count, an oral informed consent be-
fore patient screening was obtained by the medical
doctor after thorough and comprehensible explanation
of the aims and the protocol of the clinical trial.
Participants
Patients presenting CL lesions with Leishmania-positive
Giemsa smears without prior CL treatment were in-
cluded. Exclusion criteria were: age <12 years, more than
one skin lesion (to exclude intra-individual variations in
this phase IIb analysis), lesion age >3 months, lesions
located on eye lids, lips or nose, drug addiction, co-
infection with Mycobacterium tuberculosis or HIV, and
diabetes. All patients who had agreed to participate in
this trial had respected our call regarding patients´ age,
lesion age and lesion location. No patients were lost
during the screening process due to drug addiction, tu-
berculosis, HIV infection, or diabetes. Patients not avail-
able for follow-up were also ineligible. Medical services
and drugs were free of charge and patients received no
remuneration.
Location
The trial was carried out at the Leishmania and Malaria
Centre (LMC) of the Provincial Balkh Civil Hospital
Mazar-e-Sharif treating 4,000 new CL cases every year
[20]. Before trial start the centre was renovated under
the supervision of the NGO Waisenmedizin e.V. and
equipped with a solar power system guarantying elec-
trical power supply for 24 h per day.
Data capture system
Cameras, computers, and the internet-based on- and offline
electronic case report system Leishmedoc (Waisenmedizin –
PACEM e.V. Freiburg, Germany) in combination with
Skype™ (Microsoft Corporation, Redmond, USA) commu-
nication enabled real-time trial monitoring from Germany.
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Protocol of visits
Patients were registered after informed consent (see
Ethics) with demographic details, cell phone numbers
and a patient’s identification number on a patient card.
After physical examination, the location and initial state
of the lesion were documented and referenced by the
patient’s identification number and a scale. Six visits
were scheduled in the first week, two visits per week
from weeks 2 to 4, and one visit per week thereafter
until complete wound closure. Follow-up visits were re-
quired once a month until day 180 after treatment start.
Drugs for interventional therapy
Sodium stibogluconate (3 g/30 ml) was imported from
India (Albert David Ltd., India). 4.5% (500 mM) alkaline
sodium chlorite solution for pharmaceutical use (DAC
N-055; Kyrochem GmbH, Wedemark, Germany) was di-
luted in the constituent formulas of the poly-acrylate
jelly and basic crème (Additional files 1 and 2). The
German DAC N-055 contains peroxides [21] (Na2Cl2O6
and NaCClO6) at an app. 1:10 molar ratio, if produced
from chlorine dioxide in a way to minimize the chlorate
content. DAC N-055, formerly known as TCDO, pro-
motes tissue regeneration, as does hydrogen peroxide at
concentrations <10−5 M [22,23]. In contrast to hydrogen
peroxide, DAC N-055 is catalase (EC 1.11.1.6) resistant
[24]. Vials of sterile distilled water and 1% lidocaïne were
purchased from local pharmacies in Mazar-e-Sharif. Jel-
lies were freshly prepared every day by the dermatologist
(IS) of the Balkh Province Civil Hospital of Mazar-e-Sharif,
who had been trained in the Unguator® Technology
(GAKO® International GmbH, Munich, Germany) at
the Pharmaceutical Institute of the University Freiburg,
Germany. EuRho® DAC 2003 cream (Euro OTC Pharma
GmbH, Bönen, Germany) is a magistral preparation avail-
able in German pharmacies (Additional file 2).
Other drugs
In case of clinically diagnosed wound infections, topical
wound disinfection was allowed for 5 consecutive days
with saline containing 970 ppm chlorine dioxide (freshly
prepared by acidification of 0.27 % DAC N-055 in
physiological saline to pH 5). In case of failure, a sys-
temic therapy with antibiotics or with anti-mycotics of
little anti-parasitic effect was recommended. Prontosan®
(B. Braun Medical AG, Sempach, Switzerland) with the
detergent undecylenamidopropyl betaïne (CAS 133798-12-
6) at a concentration of 0.1 % was used for gently sloughing
off crusts after SSG injections to detect complete epithelia-
lisation (Figure 1).
Medical devices for interventional therapy
The electrosurgical Minicutter™ with a specially designed
bipolar angled forceps with a 1 mm distance holder and
a maximum bipolar current mode of 70 mA (HMC 80
HF Chirurgie, KLS Martin, Umkirch, Germany) was
imported from Germany.
Randomization
The LMC principal dermatologist investigator (IS) deter-
mined the patients’ eligibility. Each patient was randomly
assigned to one of the three regimens by the random
allocation generator in the computer-based Leishmedoc
system.
Treatment protocols
The patients’ OWCL lesion was treated (1) by intrader-
mal injections of 0.6 ml SSG according to a protocol
used by Zeglin (2009) [25] (Group I), or (2) by aseptic
MWT with 0.045% DAC N-055 following a single initial
superficial wound debridement with HF-EC which was
performed under local anaesthesia after wound cleansing
and disinfection with gauzes soaked in physiological
saline solution containing 320 ppm chlorine dioxide
(pH 5.5 acidified 0.09% DAC N-055) for 15 minutes
(Group II), or (3) by MWT with 0.045% DAC N-055
alone (Group III).
The topical treatment schedule was identical in all
three regimens: daily treatments (with the exception of
Fridays) during the first week, followed by topical treat-
ments at the LMC twice a week until the end of week 4
and thereafter once a week until wound closure. In
Figure 1 Photo-documentation of wound epithelialization of crusted lesions after removal of the crusts. (Panel a) Lesion status prior to
the start of the intradermal SSG treatment start at day 0; (Panel b) Lesion status after 12 intradermal SSG injections on day 51; (Panel c) Lesion
status after gentle sloughing off with Prontosan® detergent on day 90. Crusts, that were close to slough off, were removed after 30 min
incubation with aseptic 0.1% Prontosan® containing the detergent undecylenamidopropyl betaine. Afterwards, the wound was photo-documented
including the patient´s identification number and a linear scale to analyse the wound size.
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Group I, the SSG treatment was discontinued after week
4. In Groups II and III, patients dressed their lesion
themselves after week 4 with the topical NaClO2-basic-
crème between their visits at the LMC until lesion
closure.
The HF-EC debridement started with a superficial co-
agulation of the epidermis using the strongest relative
current of the Minicutter™ (position 10) for approxi-
mately two seconds necessary to boil off the excess
physiological saline on the lesion. After the coagulated
epidermis was mechanically removed with moist gauze,
the parasite infected dermal layer became visible as a
reddish granulomatous area and was specifically targeted
by a second coagulation until the area turned into a
slightly brownish colour. This procedure was performed
only once. The wounds of Groups II and III were dressed
with a EuRho® DAC 2003 cream preparation (Additional
file 2) until lesion closure, with the exception of Group II,
in which for 6 days after HF-EC debridement of the CL
lesions the wounds were daily dressed with freshly pre-
pared poly-acrylate jelly containing 0.045% DAC N-055
(Additional file 1).
During week 1, patients of Groups II and III and their
relatives were trained to dress wounds, receiving 10 g
EuRho® DAC 2003 cream containing 0.045% DAC N-
055, in a sterile syringe, which allowed self-treatment for
3 weeks.
Parasitological analyses and Leishmania species
determination
At the LMC, Leishmania parasites within the lesion
were confirmed with the slit-skin method described by
Al Hucheimi [26]. In addition, skin biopsies were taken
from the margins of the lesions and placed into modified
Schneider’s Drosophila insect medium, transported with
the German Army to the Microbiology Institute in
Erlangen, Germany, where mini-exon polymerase chain
reaction (PCR) and multiple restriction fragment length
polymorphism analyses for parasite species determin-
ation and limiting dilution analyses for determination of
the parasite loads per gram biopsy tissue were carried
out as previously described [12].
Outcome
The primary outcome of the study was the ratio of
closed versus open wounds at day 75 (D75) in the PP
analysis for each regimen.
Sample size
The specific hypotheses were (i) that the proportion of
primary closed lesions before D75 is significantly higher
in patients treated with HF-EC with subsequent MWT
using 0.045% DAC N-055 (Group II) than in patients
who received topical intradermal SSG (Group I); and (ii)
that MWT with 0.045% DAC N-055 alone, which is
known to exert tissue regenerative activity in vivo [3,18],
also promotes the closure of chronic Leishmania lesions
(Group III).
The sample size calculation was based on the per-
protocol (PP) analysis, defined as all patients evaluable
with respect to the primary endpoint. Based on the
Reithinger [13] trial and our previous findings in Kabul
[12] we defined D75 as endpoint to evaluate a clinically
relevant difference of 40% between the percentage of
wound closures in Group I (50% at D75) and Group II
(90% at D75), respectively. We assumed that SSG
chemotherapy does not directly accelerate the wound
healing process. In Group III a percentage of 75% at
D75 was estimated, since MWT promotes wound
healing. A power calculation based on Group I and II
showed that 42 patients were needed in each arm to re-
ject the null hypothesis of equal cure rates with a 90%
probability using the Fisher’s exact test (Type I error
probability 1%). An interim analysis was planned when
50% of the patients (42/2 = 21) had efficacy assessments.
Bonferroni adjustment was used to calculate p1 = 2pmin,
where pmin was the smallest of pGroup I vs Group II versus
pGroup I vs Group III [27]. Based on the pre-specified stop-
ping boundaries α1 = 0.01, β1 = 0.15 and α2 = 0.1871 and
decision rules (Additional file 3), the trial could be
stopped at stage I for efficacy.
Statistical analysis
The present trial is a phase IIb efficacy assessment trial.
The intention-to-treat analysis (ITT) is solely added as add-
itional information. Patients that could not be evaluated
were patients that were lost immediately after registration
before treatment started. Within the group of evaluable pa-
tients we distinguished between patients whose lesion could
be evaluated with respect to D75 and those that were lost
to follow-up before D75 with no wound closure. The
former were included in the per-protocol-analysis (PP) and
the latter were additionally included in the ITT. Screened
patients lost immediately after registration, were not in-
cluded in our definition of the ITT analysis.
Baseline characteristics were analysed using the Pear-
son Chi-Square Test or the Kruskal-Wallis Test. Primary
outcome was evaluated using the Fisher’s Exact Test.
Wound closure times were calculated with Kaplan-Meier
survival analysis. Hazard ratios and potential covariates
were analysed with Cox-Regression. Re-ulceration rates
were compared using the Pearson Chi-Square Test.
Statistical analyses were performed with IBM® SPSS® Sta-
tistics version 21 (IBM Deutschland GmbH, Ehningen,
Germany), except the statistics on the Leishmania load per
gram biopsy tissue that were calculated with GraphPad
Prism version 4.0 (Graphpad Software Inc., La Jolla,
CA, USA).




In total, 87 patients were enrolled, with 24 (27.5%), 32
(36.8%), and 31 (35.6%) in Groups I, II, and III, respect-
ively (Figure 2). 81 out of 87 patients (93.1%) were suit-
able for the ITT and 69 (79.3%) for the PP analysis
(Additional file 4).
Recruitment
Patients were enrolled from November 2009 to August
2010. The efficacy value of p1 was found smaller than
the stopping boundary of α1 = 0.01 pre-defined in the
protocol. Therefore the study was stopped (Additional
file 3).
Baseline data
Sixty-nine patients (37 [54%] females, 32 [46%] males)
with a mean age of 29 years (CI 25–33) followed the
protocol. The analysed baseline data were comparable in
all three regimens in the PP (Table 1) as well as ITT
analysis (Table 2). In 44 out of 69 patients analysed, 28
(64%) lesions were infected with L. tropica and 16
(36%) with L. major. L. major infections dominated from
September to March, L. tropica from March to August.
Primary outcome
15 out of 23 (65%), 23 out of 23 (100%), and 20 out of
23 (87%) patients attained complete epithelialisation
until D75 in Groups I, II and III, respectively (Group I
Figure 2 Flow chart summarizing the enrolment, randomization, and follow-up of study patients.
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versus II: p = 0.004 [PP]; Table 3). For the intention to
treat results see Table 4.
Secondary outcome
The frequent attendance of the study participants allowed
plotting wound survival curves (Figures 3 and 4). In a
Kaplan-Meier analysis (days until primary wound closure),
the survival curves of the three investigated treatments dif-
fered significantly in an overall comparison (p = 0.000039
[PP]; p = 0.000616 [ITT], Log-Rank [Mantel-Cox] test). In
the ITT analyses, mean and median lesion wound survival
times in Group II (35 [CI 30–40]/34 days [CI 29–39]) were
significantly different from those in Group I (69 days [CI
50–90]/63 days [CI 50–75]) (Tables 5 and 6); in contrast,
the pair-wise comparison of the Group III versus Group I
survival times did not reveal significant differences (p =
0.508, Log-Rank [Mantel-Cox] test) (Tables 5 and 6). In the
PP analysis, pair-wise comparison for all three groups
showed significant differences in wound survival time (p =
0.023 [Group II vs. III]; p = 0.047 [Group III vs. I], Log-
Rank [Mantel-Cox] test) (Tables 6 and 7). Hazard ratios of
Group II versus Group I equaled to 4.415 (CI 2.219-8.783)
in the PP (p = 0.000023) and 3.270 (CI 1.687-6.341) in the
ITT analysis (p = 0.000453). The lesion closed three to four
times faster in Group II than in Group I.
Covariates analysis
In the Cox-regression analysis, gender, age of the patient
age, and age of the lesion were no significant covariates
for primary closure. Lesion size at baseline was a signifi-
cant (p = 0.016) covariate with a hazard ratio of 0.883
(CI 0.798-0.977) in the PP, but not in the ITT analysis
(p = 0.312) with a hazard ratio of 0.954 (CI 0.872-1.045).
Non-desired effects (NDEs)
In the PP analysis, re-ulceration rates were similar in
Group I (four patients) and in Group II (three patients),
but were more frequent in Group III (seven patients)
(p = 0.312, Pearson Chi-Square test). No final closure
was documented for two patients (D131 and D269), one
patient (D186), and five patients (D90, D142, D143,
D143, D176) in Groups I, II, and III respectively. The
Table 1 Baseline characteristics of the PP patients enrolled in the three treatment groups of the trial
Per protocol (PP) evaluation Test
Group I Group II Group III Total p-value
Male 13 8 11 32 Pearson Chi-Square
Female 10 15 12 37 0.372* Test (Exact-Sig.)
Age (95% CI) 26 (19–34) 28 (22–33) 33 (25–40) 29 (25–33) 0.308* Kruskal-Wallis Test
Lesion age (95% CI) 9 (7–11) 8 (7–10) 7 (6–9) 8 (7–9) 0.437* Kruskal-Wallis Test
Lesion size (95% CI) 3.7 (2.3-5.0) 2.5 (1.7-3.3) 3.0 (2.0-4.1) 3.1 (2.5-3.7) 0.421* Kruskal-Wallis Test
Parasite species
L. major 4 5 7 16
L. tropica 5 13 10 28 Pearson Chi-Square
Not determined 14 5 6 25 0.664* Test (Exact-Sig.)
Lesion location
Head 5 3 2 10
Trunc 0 0 1 1
Upper extr. 12 16 14 42 Pearson Chi-Square
Lower extr. 6 4 6 16 0.666* Test (Exact-Sig.)
Parasite load according to
Giemsa staining
Low (+) 12 11 8 31
Moderate (++) 8 12 14 34
High (+++) 1 0 1 2 Pearson Chi-Square
Not determined 2 0 0 2 0.541* Test (Exact-Sig.)
Biopsy prior to treatment
Evaluable 16 18 17 51 Pearson Chi-Square
Not evaluable 7 5 6 18 0.940* Test (Exact-Sig.)
Parasite load/g tissue (SEM) 2.944 (1.645) × 106 3.081 (1.980) × 106 2.773 (1.785) × 106 2.935 (1.032) × 106 0.636* Kruskal-Wallis Test
Statistical tests were used as indicated (p < 0.05 indicates a significant proportion, *p-values refer to observations with complete information).
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number of patients in the three arms of this trial was to
small to make a meaningful comparison as to which treat-
ment mode yields the best cosmetic scar outcome. How-
ever, in Group II, the flat scars showed the typical livid
borders with hypo-pigmented central zones, taking weeks
to months to fade away as also observed in our previous
phase IIa trial in Kabul [12]. In Group II, two scar keloïds
(8.6%, 4 mm in diameter) formed at D172 and D239.
Discussion
This phase IIb study was conducted according to the
state of the art in the analysis of chronic wound
healing [28,29] and anticipated recommendations
for RCTs in CL [30]. Rapid healing in Group II
confirmed the robustness of the findings in the Kabul
trial [12].
Limitations
By its nature the present trial could not be conducted as
either a double or a single blinded trial due to the phys-
ical nature of the applied interventions.
Table 2 Baseline characteristics of the ITT patients enrolled in the three treatment groups of the trial
Intention to treat (ITT) evaluation Test
Group I Group II Group III Total p-value
Male 14 12 15 41 Pearson Chi-Square
Female 10 17 13 40 0.446* Test (Exact-Sig.)
Age (95% CI) 26 (19–33) 28 (23–33) 32 (25–38) 29 (25–32) 0.252* Kruskal-Wallis Test
Lesion age (95% CI) 9 (7–10) 9 (8–11) 7 (6–8) 8 (7–9) 0.187* Kruskal-Wallis Test
Lesion size (95% CI) 3.6 (2.3-4.9) 2.3 (1.7-3.0) 2.7 (1.8-3.6) 2.8 (2.3-3.4) 0.204* Kruskal-Wallis Test
Parasite species
L. major 5 7 9 21
L. tropica 5 14 11 30 Pearson Chi-Square
Not determined 14 8 8 30 0.614* Test (Exact-Sig.)
Lesion location
Head 5 4 4 13
Trunc 0 0 1 1
Upper extr. 12 19 16 47 Pearson Chi-Square
Lower extr. 7 5 7 19 0.799* Test (Exact-Sig.)
Parasite load according to Giemsa staining
Low (+) 13 16 11 40
Moderate (++) 8 13 16 37
High (+++) 1 0 1 2 Pearson Chi-Square
Not determined 2 0 0 2 0.534* Test (Exact-Sig.)
Biopsy prior to treatment
Evaluable 17 23 22 62 Pearson Chi-Square
Not evaluable 7 6 6 19 0.800* Test (Exact-Sig.)
Parasite load/g tissue (SEM) 2.773 (1.554)x106 3.430 (1.736)x106 2.368 (1.526)x106 2.889 (0.932)x106 0.691* Kruskal-Wallis Test
Statistical tests were used as indicated (p < 0.05 indicates a significant proportion, * p-values refer to observations with complete information).
Table 3 Per protocol analysis of the primary endpoint
Per protocol (PP) evaluation
Group I Group II Group III Total p-value
< D75 15 23 20 58
≥ D75 8 0 3 11 0.004*
Unknown NA NA NA NA
Total 23 23 23 69
*Pearson Chi-Square Test (Exact-Sign).
Table 4 Intention to treat analysis of the primary
endpoint
Intention to treat (ITT) evaluation
Group I Group II Group III Total p-value
< D75 15 23 20 58
≥ D75 8 0 4 12
Unknown 1 6 4 11 0.009*
Total 24 29 28 81
*Pearson Chi-Square Test (Exact-Sign).
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Figure 3 Wound closure time in PP patients of Group I versus Group II versus Group III. Statistically significant difference between Group II
versus Group I (p = 0.000001, Log-Rank [Mantel-Cox] test). Statistical significant differences were found between all groups (see Table 6).
Figure 4 Wound closure time in ITT patients of Group I versus Group II versus Group III. Statistically significant difference between Group
II versus Group I (p = 0.00004, Log-Rank [Mantel-Cox] test).
Stahl et al. BMC Infectious Diseases 2014, 14:619 Page 8 of 12
http://www.biomedcentral.com/1471-2334/14/619
Generalizability
So far, six physical treatment regimens have been pro-
posed and clinically tested to disinhibit the healing delay
of chronic wounds. In CL ulcers, thermotherapy (TT)
[13,31,32] sparing host tissue, photodynamic therapy
(PDT) [33-35] producing tissue 1O2 [36], cryotherapy
(N2) [37-39], CO2 laser [40-43], and HF-EC [12] all
elicited short-term constructive inflammatory reactions
with beneficial ROS production in the tissue [44] and
destroyed parasites and commensal bacteria together
with host cells. Similarly, CAP presumably also acted by
forming ROS in non-CL skin lesions [45,46]. After initial
debridement by HF-EC CL ulcers healed despite of re-
sidual, persisting parasites, and MWT treatment with
pharmaceutical chlorite showed an additional beneficial
healing effect in lesions with high pre-treatment parasite
loads [12]. In 2008, González et al. highlighted on page
33 of their Cochrane meta-analysis: “We found no RCTs
on the use of wound healing to treat OWCL” [47]. This
initiated the introduction of MWT with 0.045% DAC N-
055 alone as third regimen in the present RCT, without
previous HF-EC treatment.
Interpretation
Pharmaceutical chlorite did not shorten wound-healing
times in the Kabul trial [12], when it was performed
after HF-EC wound debridement, which already pro-
moted wound granulation to a maximum extent. How-
ever, in spite of the small sample size of the present trial,
MWT with 0.09% DAC N-055 alone showed a signifi-
cantly shorter wound closure time in the PP analysis
than topical anti-parasitic SSG, suggesting that pharma-
ceutical chlorite has an intrinsic effect on wound heal-
ing, even if such wounds result from parasitic infections.
Reactive oxygen species (ROS) seem to be prominently
involved in wound healing pathology and physiology.
At tissue levels above 10−4 M, ROS including 1O2 are
cytotoxic and may act as cell aging signals [22,48]; below a
tissue concentration of 10−5 M, ROS promote cell prolifer-
ation and tissue repair (granulation, neo-angiogenesis and
epithelialisation) [22]. This explains the dose-related
effect of NTP on mammalian cells, which produces ROS
[11], ranging from inducing apoptosis to increasing cell
proliferation [44]. This could also explain, why non-
constructive inflammation with ROS production >10−4 M
inhibits wound healing, whilst constructive inflammation
with ROS production <10−5 M promotes tissue regener-
ation and wound closures [49,50], similarly to CAP [51].
Liquid nitrogen, the CO2 laser, bipolar HF-EC, PDT,
and pharmaceutical chlorite applied to the wound [3,5,6]
or to the skin [17,18], where NaClO2 reacts with heme
or bacterial dismutases, are likely to have a common
denominator for the of wound healing, which might be
1O2 or other ROS.
0.045% DAC N-055 basic crème contains 5 mM
NaClO2 diffusing slowly into the skin and wound tissue.
For NaClO2 to act as a protracted source of
1O2 in the
range of 10−5 to 10−6 M in the wound tissue, it would be
sufficient that 1 to 10‰ of the applied DAC N-055
inoculum enters a heme-catalyzed dismutase reaction
which leads to the formation of hypochlorite and subse-
quently to 1O2. In 1984, it was apparently wrong to
speculate on pharmaceutical chlorite as a direct source
of oxygen supply for the respiratory chain [52].
Skin defects are always at risk of microbial colonization
and infection, especially in the problematic hygienic hos-
pital environment of poor countries such as Afghanistan.
Therefore, rapid wound closure is highly desirable. More-
over, physical treatment techniques have the advantage
that they do not induce parasite resistance, which is
an increasing concern for CL therapy with pentavalent
antimony [53].
In contrast to HF-EC, less intrusive therapies such as the
application of N2 or PDT are not administered in “one ses-
sion only” and require supposedly more resources. Both
the CO2 laser and bipolar HF-electrosurgery have been
used for single session debridement in patients with as
many as 4–5 lesions (Reto Steiner and KW Stahl, German
Medical Service Kabul, unpublished results). However, in
contrast to the CO2 laser, the HF-EC device is a robust
instrument with practically no maintenance costs for de-
cades. The HF-EC device can be run with a car battery in
the absence of electrical power supply. In contrast to a
Table 5 Intention to treat analysis of mean and median
wound survival time (days)
Intention to treat (ITT) evaluation
Group I Group II Group III Overall
Mean (95% CI) 69 (50–90) 35 (30–40) 66 (41–91) 58 (46–70)
Median (95% CI) 63 (50–75) 34 (29–39) 51 (17–85) 44 (32–56)
Table 6 P-values: pairwise comparison of the survival
functions
Group I Group II Group III
Group I 0.000001/0.000040 0.047032/0.507623
Group II 0.000001/0.000040 0.022813/0.013589
Group III 0.047032/0.507623 0.022813/0.013589
Log-Rank (Mantel-Cox) test, p-values refer to the per-protocol (left value) and
the intention-to-treat analysis (right value).
Table 7 Per protocol analysis of mean and median wound
survival time (days)
Per protocol (PP) evaluation
Group I Group II Group III Overall
Mean (95% CI) 69 (49–89) 33 (29–37) 45 (34–56) 49 (41–57)
Median (95% CI) 63 (47–79) 32 (27–37) 35 (21–49) 37 (31–43)
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CO2 laser, bipolar HF-EC treatment is more superficial,
allows a loophole-free destruction of the lesion tissue, and
the cauterization process is less unrestricted in space than
with laser beams, which induce deep and very narrow
thermal tissue coagulation [54]. From our experience in
Kabul with the German Medical Service (GMS), the CO2
laser seems to be especially helpful to treat multiple small
recurrent CL lesions in the face.
Already in 2005, results from murine experiments
have claimed that the wound repair response controls
the outcome of cutaneous leishmaniasis [55], but so far,
to our knowledge, this has not inspired any clinical
research work to test this hypothesis in humans. Of
course, direct extrapolation from “mice to men” is prob-
lematic and our clinical results do not give any straight-
forward answer to the question, whether mechanisms
found in the mouse model also apply to humans [56-58].
However, it is noteworthy to mention that a high degree
of microbial and fungal contaminations and superinfec-
tions have been observed in leishmanial wounds [15].
They lead to chronic inflammatory processes which
counteract the wound healing and involve peroxidase se-
cretions from macrophages and neutrophils. Interest-
ingly, recent biochemical work has shown that human
peroxidases, such as lactoperoxidase and myeloperoxi-
dase, are key targets of μM concentrations of chlorite,
which destroys these enzymes by heme catalysis [59].
Non-desired effects
Every scarring process of full thickness wounds with or
without topical CL treatment comprises an inevitable
risk of late keloïd formation. Keloïds were registered in
six (5.3%) patients within the phase IIa trial in Kabul
[12] and in two (8.7%) patients of Group II in the
present RCT. Asilian and colleagues found hypertrophic
scars in five (6%) patients treated with CO2 laser [41].
Wound healing in the absence of a strong parasitocidal
intervention (Group III) seemed to bear a higher risk of
reulcerations than observed in Groups I and II, where
parasites were killed by SSG or HF-EC, respectively. As
DAC N-055 has a strong wound healing effect, but only a
limited leishmanicidal activity notably against intracellular
parasites [12] (US and CB, unpublished data), future
clinical trials should investigate the combination of DAC
N-055 MWT with a strong leishmanicidal regimen.
Conclusions
In CL endemic regions with poor infrastructure, bipolar
HF-EC is a robust technology to debride CL lesions
under local anaesthesia. The combination with DAC N-055
MWT provides additional anti-parasitic, antimicrobial and
wound healing effects. Well designed and controlled pro-
spective cohort studies with a large sample of patients and
a post-treatment monitoring period of one to two years are
the only way of investigating the frequency and impact of
NDEs such as keloïd or hypertrophic scars, permanent
pigmental disorders, or persisting erythemas. The cost-
effectiveness of the proposed interventions is currently
under investigation.
Additional files
Additional file 1: Formula of 0.045% DAC N-055 jelly (adjusted with
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Additional file 3: Decision rules in the adaptive drop-loser statistical
sample design with α1=0.01, β1=0.15 and α2=0.1871.
Additional file 4: Patients that could not be considered in the per
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randomized patients, could not be considered in the PP analysis due to
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in the ITT analysis after being assigned to their randomized groups.
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